切换至 "中华医学电子期刊资源库"
高级检索
中华介入放射学电子杂志

中华介入放射学电子杂志 ›› 2016, Vol. 04 ›› Issue (03) : 136 -141. doi: 10.3877/cma.j.issn.2095-5782.2016.03.003

所属专题： 文献；

肿瘤介入

PVA-TACE治疗肝癌并肝动-静脉分流的疗效及生存预后
刘秋松1, 梅雀林2,†()   
  1. 1. 361004　福建厦门，厦门大学附属中山医院肿瘤与血管介入科
    2. 510515　广东广州，南方医科大学南方医院介入科
  • 收稿日期:2016-04-20 出版日期:2016-08-01
  • 通信作者: 梅雀林

Evaluation of polyvinyl alcohol transcatheter arterial chemoembolization in treating hepatocellular carcinoma with hepatic arteriovenous shunts and its prognosis

Qiusong Liu1, Quelin Mei2,†()   

  1. 1. Department of Interventional Radiology, Affiliated Zhongshan Hospital, Xiamen University, Xiamen 361004, China
    2. Department of Interventional Radiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
  • Received:2016-04-20 Published:2016-08-01
  • Corresponding author: Quelin Mei
  • About author:
    Corresponding author: Mei Quelin, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

刘秋松, 梅雀林. PVA-TACE治疗肝癌并肝动-静脉分流的疗效及生存预后[J/OL]. 中华介入放射学电子杂志, 2016, 04(03): 136-141.

Qiusong Liu, Quelin Mei. Evaluation of polyvinyl alcohol transcatheter arterial chemoembolization in treating hepatocellular carcinoma with hepatic arteriovenous shunts and its prognosis[J/OL]. Chinese Journal of Interventional Radiology(Electronic Edition), 2016, 04(03): 136-141.

目的：

探讨聚乙烯醇微粒肝动脉化疗栓塞（PVA-TACE）治疗肝细胞癌（HCC）并肝动-静脉分流（HAVS）的疗效预测及生存预后影响因素分析。

方法：

回顾性分析113例HCC并HAVS，依据分流速度不同采用不同规格PVA化疗栓塞。依据疗效分为肿瘤控制组（A组，63例）与肿瘤进展组（B组，50例），随访并分析生存期，采用Kaplan-Meier法计算累积生存率，疗效预测因素采用多因素logistic回归分析，生存预后因素采用Cox模型分析。

结果：

113例患者的中位生存期（OS）为11.0个月。A、B组中位OS分别为14.5个月、9.2个月，两组患者的生存期差异有统计学意义（χ2=15.215，P<0.001）。多因素logistic回归分析显示：肿瘤分布于单叶（OR=0.222，P=0.003）及无癌栓形成（OR=0.126，P=0.024）患者的疗效较好。多因素Cox回归分析显示：年龄≤50岁（HR=0.616，P=0.049）、多次栓塞治疗（HR=0.550，P=0.039）及肿瘤控制（HR=0.443，P=0.002）为预后的独立保护因素，而肿瘤负荷>50%（HR=3.156，P<0.001）及分流栓塞程度较低（HR=2.011，P=0.002）为预后的独立危险因素。

结论：

PVA-TACE治疗HCC并HAVS是安全、有效的。肿瘤单叶分布及无血管癌栓侵犯肿瘤控制较好。肿瘤负荷较大及分流栓塞程度较低患者预后较差，年轻、多次栓塞治疗及肿瘤控制的患者预后较好。

关键词: 癌，肝细胞, 动-静脉分流, 生存预后, 聚乙烯醇, 肝动脉化疗栓塞术
Objective:

To evaluate the efficacy of polyvinyl alcohol transcatheter arterial chemoembolization (PVA-TACE) in the treatment of hepatocellular carcinoma (HCC) with hepatic arteriovenous shunts (HAVS) and its prognosis among these patients.

Methods:

113 patients with HCC and HAVS were collected who were divided into two groups according to their responding to the therapeutics-group A (tumor control, n=63) and group B (tumor progress, n=50). Based on HAVS types, different sizes of PVA were used to embolize the shunts accordingly. The overall survival (OS) was analyzed in the follow-up study. Factors associated with efficacy were evaluated using multivariate logistic regression analysis. The survival prognostic factors were assessed by multivariate Cox analysis.

Results:

The median OS of 113 patients was 11.0 months. The median OS of the group A and group B patients were 14.5 months and 9.2 months, respectively. The survival curves of the two groups were estimated by the Kaplan–Meier method and compared by a Log-rank test, which revealed a significant difference between two groups (χ2=15.215, P<0.001). On multivariate logistic analysis, tumor location (OR=0.222, P=0.003) and tumor thrombosis (OR=0.126, P=0.024) were significant factors for efficacy. Independent prognostic factors for a longer survival included: patient age ≤50 years (HR=0.616, P=0.049), multiple embolization (HR=0.550, P=0.039) and tumor control (HR=0.443, P=0.002). While tumor burden >50% (HR=3.156, P<0.001) and lower level of shunts occlusion were considered independent risk factors.

Conclusions:

PVA-TACE is a safe and effective strategy for HCC with HAVS , especially for single-lobe tumor and without tumor thrombosis. Younger age, multiple embolization and tumor control show a better survival prognosis. Patients with tumor burden>50% and lower level of shunts occlusion show a poor survival prognosis.

Key words: carcinoma, hepatocellular, arteriovenous shunts, prognosis, polyvinyl alcohol
表1 肿瘤控制组和肿瘤进展组患者的基线情况
参数 A组（63例） B组（50例） χ2值 P值
中位年龄 ≤50岁 28 30 2.676 0.102
? >50岁 35 20 ? ?
肿瘤分布 单叶 55 32 8.469 0.004
? 双叶 8 18 ? ?
肿瘤边界 局限型 53 35 3.203 0.074
? 浸润型 10 15 1.109 0.292
肿瘤负荷 ≤50% 39 26
? >50% 24 24
BCLC分期a A 4 0 0.796 0.372
? B 8 14 ? ?
? C 51 36 ? ?
血管癌栓形成 无 14 17 1.741 0.187
? 有 49 33 ? ?
AFP水平（μg/L） <400 29 17 1.657 0.198
? ≥400 34 33 ? ?
图1 肿瘤控制组和肿瘤进展组的累积生存曲线图
图2 患者男，52岁，原发性肝癌（块状型），中速型肝动脉-门静脉分流及肝动脉-肝静脉分流
图3 患者男，69岁，原发性肝癌（巨块型）合并门静脉右支、肝右静脉癌栓形成，中速型肝动脉-肝静脉分流
表2 PVA-TACE治疗HCC合并HAVS的疗效的影响因素分析
因素 B SE Waldχ2 P值 OR（95%CI）
术前BCLC分期a -1.432 0.835 2.944 0.086 0.239（0.046～1.226）
AFP -0.733 0.445 2.707 0.100 0.481（0.201～1.150）
肿瘤边界 -0.928 0.518 3.210 0.073 0.395（0.143～1.091）
肿瘤分布 -1.506 0.510 8.719 0.003 0.222（0.082～0.603）
癌栓形成 -2.071 0.920 5.073 0.024 0.126（0.021～0.764）
表3 影响HCC合并HAVS患者生存期的单、多因素分析
因素 单因素分析 多因素分析
χ2 P值 HR 95%CI P值
年龄 3.522 0.061 0.616 0.380～0.998 0.049
肿瘤负荷 18.016 <0.001 3.156 1.930～5.162 <0.001
栓塞次数 11.929 0.001 0.550 0.311～0.971 0.039
分流栓塞程度 7.678 0.053 2.011 1.279～3.161 0.002
奥沙利铂总量 5.858 0.016 ? ? ?
肿瘤控制情况 15.215 <0.001 0.443 0.262～0.748 0.002
1
Ngan H, Peh WC. Arteriovenous shunting in hepatocellular carcinoma: its prevalence and clinical significance[J]. Clin Radiol, 1997, 52(1): 36-40.
2
Oh D, Shin SW, Park HC, et al. Changes in arterioportal shunts in hepatocellular carcinoma patients with portal vein thrombosis who were treated with chemoembolization followed by radiotherapy[J]. Cancer Res Treat, 2015 ,47(2):251-258. doi: 10.4143/crt.2014.011.
3
孙磊, 施海彬, 刘圣, 等. 肝细胞癌肝动脉门静脉分流形成的相关因素分析[J]. 介入放射学杂志, 2012, 21(3): 206-210. doi:10.3969/j.issn.1008-794X.2012.03.008.
4
Kim YJ, Lee HG, Park JM, et al. Polyvinyl alcohol embolization adjuvant to oily chemoembolization in advanced hepatocellular carcinoma with arterioportal shunts[J]. Korean J Radiol, 2007, 8(4): 311-319.
5
刘秋松, 梅雀林, 李彦豪, 等. 聚乙烯醇微粒末梢性化疗栓塞肝细胞癌合并肝动静脉分流的疗效与安全性[J]. 中华放射学杂志, 2015, 49(10): 763-768. doi:10.3760/cma.j.issn.1005-1201.2015.10.010.
6
Mei Q, Li Y. Transcatheter arterial embolization of hepatic arteriovenous shunts in patients with hepatocellular carcinoma[J]. Semin Intervent Radiol, 2012 ,29(3):237-240. doi: 10.1055/s-0032-1326935.
7
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010,30(1):52-60. doi: 10.1055/s-0030-1247132.
8
欧阳墉, 欧阳雪晖. 肝内肝动脉-门静脉分流的研究进展[J]. 医学影像学杂志, 2005, 15(12): 1019-1023. doi:10.3969/j.issn.1006-9011.2005.12.001.
9
张凯, 王茂强, 李彩霞, 等. α-氰丙烯酸正丁酯治疗肝癌高流量动脉-门静分流的临床研究[J]. 中国医学影像学杂志, 2010, 18(6): 543-546.
10
Takizawa D, Kakizaki S, Sohara N, et al. Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis[J]. Dig Dis Sci, 2007, 52(11): 3290-3295.
11
Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study[J]. Ann Surg Oncol, 2011,8(2):413-420. doi: 10.1245/s10434-010-1321-8.
12
Jia L, Kiryu S, Watadani T, et al. Prognosis of hepatocellular carcinoma with portal vein tumor thrombus:assessment based on clinical and computer tomography characteristics[J]. Acta Med Okayama, 2012, 66(2): 131-141.
13
周卫忠, 刘圣, 杨正强, 等. 氰基丙烯酸酯胶栓塞原发性肝细胞癌合并重度肝动脉门静脉瘘12例疗效分析[J]. 介入放射学杂志, 2013, 22(8): 641-645. doi:10.3969/j.issn.1008-794X.2013.08.007.
14
Murata S, Tajima H, Nakazawa K, et al. Initial experience of transcatheter arterial chemoembolization during portal vein occlusion for unresectable hepatocellular carcinoma with marked arterioportal shunts[J]. Eur Radiol, 2009, 19(8): 2016-2023. doi: 10.1007/s00330-009-1349-y.
15
Chung SM, Yoon CJ, Lee SS, et al. Treatment outcomes of transcatheter arterial chemoembolization for hepatocellular carcinoma that invades hepatic vein or inferior vena cava[J]. Cardiovasc Intervent Radiol, 2014,37(6):1507-1515. doi: 10.1007/s00270-014-0841-1.
16
刘秋松,张恭良,梅雀林,等.PVA-TACE治疗肝细胞癌并肝肺分流的临床疗效预后分析[J].中华介入放射学电子杂志,2016,4(2):71-76.doi:10.3877/cma.j.issn.2095-5782.2016.02.004.
17
Vogl TJ, Nour-Eldin NE, Emad-Eldin S, et al. Portal vein thrombosis and arterioportal shunts: effects on tumor response after chemoembolization of hepatocellular carcinoma[J]. World J Gastroenterol, 2011,17(10):1267-1275. doi: 10.3748/wjg.v17.i10.1267.
18
Shi HB, Yang ZQ, Liu S, et al. Transarterial embolization with cyanoacrylate for severe arterioportal shunt complicated by hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol, 2013,36(2):412-421. doi: 10.1007/s00270-012-0410-4.
19
Zhou WZ, Shi HB, Liu S, et al. Arterioportal shunts in patients with hepatocellular carcinoma treated using ethanol-soaked gelatin sponge: therapeutic effects and prognostic factors[J]. J Vasc Interv Radiol, 2015,26(2):223-230. doi: 10.1016/j.jvir.2014.11.002.
20
Hu HT, Kim JH, Lee LS, et al. Chemoembolization for hepatocellular carcinoma: ultivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort[J]. J Vasc Interv Radiol, 2011,22(7):917-923. doi: 10.1016/j.jvir.2011.03.005.
[1] 中国医师协会肝癌专业委员会. 肝细胞癌伴微血管侵犯诊断和治疗中国专家共识（2024版）[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 313-324.
[2] 汤宏涛, 何坤. 中晚期肝细胞癌介入治疗的进展及前景[J/OL]. 中华普通外科学文献(电子版), 2024, 18(04): 305-308.
[3] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[4] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[5] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[6] 公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[7] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[8] 刘敏思, 李荣, 李媚. 基于GGT与Plt比值的模型在HBV相关肝细胞癌诊断中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 831-835.
[9] 焦振东, 惠鹏, 金上博. 三维可视化结合ICG显像技术在腹腔镜肝切除术治疗复发性肝癌中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 859-864.
[10] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[11] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[12] 吴警, 吐尔洪江·吐逊, 温浩. 肝切除术前肝功能评估新进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 889-893.
[13] 邓万玉, 陈富, 许磊波. 肝硬化与非肝硬化乙肝相关性肝癌患者术后无复发生存比较及其影响因素分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 670-674.
[14] 王向前, 李清峰, 陈磊, 丘文丹, 姚志成, 李熠, 吴荣焕. 姜黄素抑制肝细胞癌索拉非尼耐药作用及其调控机制[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 729-735.
[15] 蔡晓雯, 李慧景, 丘婕, 杨翼帆, 吴素贤, 林玉彤, 何秋娜. 肝癌患者肝动脉化疗栓塞术后疼痛风险预测模型的构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 722-728.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号